Maleriya debases treatment medicine
Reading File
Malaria treatment covers a broad topic. Let me search the medical library for comprehensive coverage.
Finding Sources
Finding Sources
Searching PubMed
"malaria" AND "treatment" AND "antimalarial"
Good results. Now let me read the key sections from multiple textbooks in parallel.
Reading File
Reading File
Reading File
Now let me read the severe malaria treatment section from Harrison's and the Goldman-Cecil treatment table.
Reading File
Reading File
I now have excellent, comprehensive information from multiple authoritative textbooks. Let me compile the full answer.
Malaria (Malaria) - Disease Treatment
Overview of Malaria Species
Malaria is caused by five Plasmodium species that infect humans:
- P. falciparum - most dangerous, causes severe/cerebral malaria
- P. vivax - forms hypnozoites (liver dormant stage), can relapse
- P. ovale - also forms hypnozoites, relapse possible
- P. malariae - milder, no relapses from liver
- P. knowlesi - zoonotic, treated like falciparum
1. Uncomplicated Malaria Treatment
P. falciparum (and P. knowlesi)
First-line: Artemisinin-Based Combination Therapy (ACT)
The WHO recommends ACT as first-line treatment for all uncomplicated P. falciparum malaria worldwide. ACT pairs a fast-acting artemisinin derivative with a longer-acting partner drug:
| ACT Regimen | Artemisinin Component | Partner Drug | Notes |
|---|---|---|---|
| Artemether-Lumefantrine (Coartem) | Artemether | Lumefantrine | Most widely used globally |
| Artesunate + Amodiaquine | Artesunate | Amodiaquine | Used in Africa |
| Artesunate + Mefloquine | Artesunate | Mefloquine | SE Asia |
| Artesunate + Sulphadoxine-Pyrimethamine (AS+SP) | Artesunate | SP | India (standard); replaced by AL in NE states due to SP resistance |
| Dihydroartemisinin + Piperaquine (DHA-PPQ) | Dihydroartemisinin | Piperaquine | Asia |
India-specific (National Program): ACT (Artesunate 3 days + Sulphadoxine-Pyrimethamine 1 day) + single dose Primaquine 0.75 mg/kg on Day 2 for all confirmed P. falciparum. In NE states (due to SP resistance): Artemether 20 mg + Lumefantrine 120 mg (co-formulated tablet). - Park's Textbook of Preventive and Social Medicine
Artemisinin monotherapy is banned - it promotes resistance development.
P. vivax, P. ovale (Chloroquine-Sensitive Areas)
- Chloroquine 25 mg/kg divided over 3 days (blood stage)
- + Primaquine 0.25 mg/kg/day x 14 days - to eliminate hypnozoites and prevent relapse
Caution with Primaquine: Contraindicated in G6PD-deficient patients (causes hemolytic anemia), infants, and pregnant women. Always screen for G6PD deficiency before use. Watch for: dark urine, jaundice, cyanotic lips, abdominal pain - stop immediately if these appear. - Park's Textbook
Chloroquine-resistant P. vivax (parts of Indonesia, Oceania, SE Asia, South/Central America): Use ACT instead.
P. malariae
- Chloroquine alone (no hypnozoites, no relapse from liver)
- No primaquine needed for radical cure
Mixed Infections (P. falciparum + P. vivax)
- Treat as falciparum malaria (ACT covers both species)
2. Severe/Complicated Malaria Treatment
Criteria for Severe Malaria (Any one feature = severe):
| Feature | Threshold |
|---|---|
| Impaired consciousness / coma | - |
| Repeated generalized convulsions | - |
| Renal failure | Serum creatinine >3 mg/dL |
| Jaundice | Serum bilirubin >3 mg/dL |
| Severe anaemia | Hb <5 g/dL |
| Pulmonary oedema / ARDS | - |
| Hypoglycaemia | Plasma glucose <40 mg/dL |
| Metabolic acidosis | - |
| Circulatory collapse / shock | Systolic BP <80 mmHg (adults), <50 mmHg (children) |
| Abnormal bleeding / DIC | - |
| Haemoglobinuria | - |
| Hyperthermia | >106°F / 42°C |
| Hyperparasitaemia | >5% parasitized RBCs (low endemic), >10% (hyperendemic) |
Drug of Choice: Parenteral Artesunate
In large RCTs, IV artesunate reduced mortality by 35% in Asian adults/children and 22.5% in African children compared to quinine. Artesunate is now the drug of choice for ALL patients with severe malaria. - Harrison's Principles of Internal Medicine, 22nd Ed.
Regimen:
- IV/IM Artesunate - given immediately upon diagnosis (do not wait for lab results)
- Once the patient can take oral medications, complete treatment with a full course of ACT
- Quinine (IV/IM): alternative if artesunate unavailable; given with doxycycline/tetracycline/clindamycin
Before transfer/referral: Give a pre-referral dose of parenteral artemisinin derivative or quinine (whichever is available), take blood smear and RDT.
3. Special Populations
Pregnancy
| Trimester | P. falciparum | P. vivax |
|---|---|---|
| 1st trimester | Quinine (ACT avoided) | Chloroquine |
| 2nd & 3rd trimesters | ACT | Chloroquine |
- Primaquine is contraindicated in all trimesters
- Severe malaria in pregnancy: IV artesunate per general guidelines (weigh risks)
- Breastfeeding: Chloroquine/hydroxychloroquine preferred; atovaquone-proguanil only if infant >5 kg with normal G6PD
Children
- Same drug classes as adults; doses are weight-based
- Pediatric dose should never exceed adult dose
- Tetracycline/doxycycline: avoid in children <8 years (except emergencies)
- Atovaquone-proguanil as treatment: approved only for children >5 kg
- Malnourished/younger children require higher weight-adjusted doses
4. Drug Resistance
- Chloroquine resistance in P. falciparum: Widespread globally (except Central America, Haiti, Middle East)
- Artemisinin resistance in P. falciparum: Emerged in SE Asia (Greater Mekong Subregion) in late 2000s; now spreading to East Africa - major emerging threat
- Molecular markers: Pfkelch13 mutations (artemisinin resistance), Pfcrt mutations (chloroquine), Pfpm1/2 amplification (piperaquine), Pfmdr1 amplification (mefloquine)
- ACT treatment failure (no response within 72 hours despite full course + no vomiting/diarrhea): Switch to oral quinine + tetracycline/doxycycline
- Proposed solution for resistance: Triple ACTs (two slowly-eliminated partner drugs) are being evaluated
Falsified or substandard antimalarial drugs are sold in many Asian and African countries and may cause treatment failures. - Harrison's 22E
5. Key Antimalarial Drug Summary
| Drug Class | Drugs | Mechanism | Use |
|---|---|---|---|
| Artemisinins | Artesunate, Artemether, DHA | Free radical generation via endoperoxide bridge | Backbone of ACT; fastest parasite clearance |
| 4-Aminoquinolines | Chloroquine, Amodiaquine | Heme polymerization inhibition | Vivax/ovale/malariae; partner drug in ACT |
| Amino alcohols | Mefloquine, Lumefantrine | Heme metabolism disruption | Partner drugs in ACT |
| Antifolates | Sulphadoxine-Pyrimethamine, Proguanil | DHFR/DHPS inhibition | Partner drugs (resistance spreading) |
| 8-Aminoquinolines | Primaquine, Tafenoquine | Mitochondrial disruption | Radical cure of vivax/ovale; gametocytocidal |
| Naphthoquinone | Atovaquone (+ Proguanil = Malarone) | Mitochondrial electron transport | Treatment + prophylaxis; not in pregnancy |
| Antibiotics | Doxycycline, Tetracycline, Clindamycin | Protein synthesis inhibition | Used as partner drugs in quinine regimen |
6. Chemoprophylaxis (Prevention for Travelers)
- Atovaquone-Proguanil (Malarone): Daily, start 1-2 days before travel, stop 7 days after
- Doxycycline: Daily; start 1-2 days before, stop 4 weeks after
- Mefloquine: Weekly; start 2-3 weeks before, stop 4 weeks after
- Chloroquine: Only for chloroquine-sensitive areas (limited use now)
Self-treatment abroad: If reliable diagnosis unavailable, presumptive self-treatment with atovaquone-proguanil is recommended (seek medical attention as soon as possible).
Sources: Harrison's Principles of Internal Medicine 22E (2025) | Goodman & Gilman's Pharmacological Basis of Therapeutics | Park's Textbook of Preventive and Social Medicine | Katzung's Basic and Clinical Pharmacology, 16th Ed. | Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.